The U.S. Supreme Court heard oral arguments today in Hikma v. Amarin, a closely-watched case that in part asks the Justices to weigh in on whether a drugmaker calling its product a “generic version” while citing public sales information about the branded drug induces infringement of a patented use fully carved out by the generic’s label. Hikma’s petition also asks whether a complaint states an induced infringement claim if it fails to allege any instruction or statement by the defendant mentioning the patented use. While some Justices today questioned why the case was even before them, others seemed concerned about the potential impact of the case for the generic pharmaceutical industry.
Last week, Bloomberg Law broke the news that U.S. District Judge Alan D. Albright of the Western District of Texas would leave the Western Texas bench by the end of this August. Nominated to the federal judiciary during the first Trump Administration, Judge Albright spent his relatively short time on the bench cutting a courageous pathway through patent law, which created some controversy in Congress, but notably has earned him a reputation of thoughtfulness and fairness in the application of patent law among plaintiff- and defendant-side lawyers arguing in his courtroom.
Most companies entering a joint development agreement are focused on making the project work. What they are less focused on—and what can create serious problems years down the line—is what happens to the confidential information shared during that project once it ends. That’s one of the central arguments Emily Teesdale, founder of Pivot IP, makes in a recent episode of IP Innovators.
Harrity & Harrity is expanding and seeks experienced patent attorneys or agents who thrive in handling electrical or mechanical technology. You will draft and prosecute high-value applications for world-class innovators while working remotely (in the U.S.) within a close-knit, highly collaborative team. A solid foundation in semiconductors or 5G wireless is a welcome plus.
In this episode of IPWatchdog Unleashed, I speak with Matt Johnson, Co-Chair of the PTAB Practice at Jones Day, and we take an in-depth look at the Patent Trial and Appeal Board (PTAB) nearly a decade and a half after its launch. Johnson and I discuss the ongoing PTAB reset at the United States Patent and Trademark Office (USPTO) and suggest practical fixes for a better, reengineered PTAB. The majority of the conversation is devoted to concrete, targeted reform suggestions that would lead to a better functioning PTAB and more streamlined IPR review system. Instead of abstract complaints, Johnson proposes narrowing PGR estoppel to encourage early challenges, moving IPR estoppel to the point of institution to eliminate gamesmanship, separating institution decisions from full merits adjudication to reduce confirmation bias, and rethinking quiet-title concepts to better align notice to implementers with settled expectations of patent owners.
Arnold & Porter is a leading international law firm with offices across the United States, Europe, and Asia. The firm delivers sophisticated regulatory, litigation, and transactional services to clients across a wide range of industries. Arnold & Porter is seeking a Senior Manager of IP Prosecution to join its Washington, DC office. This role provides firmwide leadership for the Intellectual Property Prosecution function, overseeing patent and trademark operations and ensuring the delivery of efficient, high-quality support to attorneys and clients.
This week on IPWatchdog Unleashed, I had the pleasure of speaking with Deborah Farone, founder of Farone Advisors, former Chief Marketing Officer of Cravath, Swain & Moore, and author of Breaking Ground: How Successful Women Lawyers Build Thriving Practices. Our conversation focused on how lawyers—particularly in highly technical fields like intellectual property—can build thriving practices through disciplined, strategic business development. The discussion underscores that business development is a skill, not an innate personality trait. Even introverted attorneys can succeed by taking incremental steps, practicing authentic communication, and focusing on listening rather than selling.
This week on IPWatchdog Unleashed, my conversation with Hilary Preston, partner at Vinson & Elkins and co-head of its intellectual property and technology litigation practice, underscores a fundamental shift underway in how sophisticated organizations approach intellectual property. What was once a reactive, litigation-centric discipline, is rapidly evolving into something far more strategic—an integrated function that sits at the intersection of technology, business, and risk management. Ultimately, what emerged from this discussion is a vision of IP practice that is far more integrated and strategic than the traditional model. It is a shift from courtroom to boardroom counselor—from reactive defense to proactive governance. For practitioners, this requires a broader skill set and a willingness to engage deeply with technology and business. For clients, it offers the promise of more effective risk management and better alignment between legal strategy and commercial objectives.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today in Constellation Designs, LLC v. LG Electronics Inc., vacating in part and affirming in part a decision of the United States District Court for the Eastern District of Texas. The CAFC determined that the district court incorrectly found the “optimization claims” of Constellation Designs, LLC’s patents directed to eligible subject matter under 35 U.S.C. § 101, but correctly found the “constellation claims” eligible.
Pharmaceutical patent litigators are no strangers to the delicate dance between the Hatch-Waxman Act and 35 U.S.C. § 271(b). On one side of this statutory tightrope lies the Hatch-Waxman Act’s Section VIII pathway, which was designed to expedite affordable generic competition by allowing manufacturers to seek Food and Drug Administration (FDA) approval solely for unpatented indications—the proverbial “skinny label.” On the flip side lies Section 271(b), which imposes strict liability on anyone who “actively induces” patent infringement.
I keep hearing the same thing from patent professionals across the industry—inside companies, inside law firms, and even from investors. Patent budgets are shrinking, expectations are rising, and nobody seems willing to admit what that combination actually means.
The UK Supreme Court today issued a landmark judgment on AI patentability that is likely to impact all software patents going forward. The decision in Emotional Perception v. Comptroller General of Patents, Designs and Trade Marks primarily held that the approach taken in Aerotel Ltd v Telco Holdings Ltd [2006] EWCA Civ 1371; [2007] Bus LR 634; [2007] RPC 7 (Aerotel) should no longer be followed. Under Aerotel, courts and examiners consider a four-step test for assessing whether a claim is excluded from patent eligibility: 1) properly construe the claim, 2) Identify the actual/ alleged contribution, 3) Ask whether the contribution is excluded and 4) check if the contribution is technical.
On Tuesday, news reports indicated that U.S. Senators Adam Schiff (D-CA) and John Curtis (R-UT) introduced the Copyright Labeling and Ethical AI Reporting (CLEAR) Act into Congress. If enacted as drafted, the bill would establish mandatory reporting requirements for companies developing artificial intelligence (AI) models that are trained using original works that are protected under U.S. copyright law, and would create an additional cause of action for copyright owners alleging that generative AI developers failed to give such notice with respect to their works.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates